Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Unverdorben

Showing results (51-60 of 76) with videos related to

Pageof 8
Sort By:
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|September 24, 2013
Treatment of small coronary arteries with a paclitaxel-coated balloon catheter in the PEPCAD I study: are lesions clinically stable from 12 to 36 months?Martin Unverdorben, Franz X Kleber, Hubertus Heuer, et al.
Journal of the American Heart Association|May 15, 2025
Comparing Major Gastrointestinal Bleeding in Patients Receiving Edoxaban Versus Warfarin After Transcatheter Aortic Valve Replacement: Results From the Randomized ENVISAGE-TAVI AF TrialGeorge D Dangas, Martin Unverdorben, Johny Nicolas, et al.
The American Journal of Cardiology|July 20, 2024
Risk Factors of Ischemic Stroke in Patients With Atrial Fibrillation After Transcatheter Aortic Valve Implantation from the Randomized ENVISAGE-TAVI AF TrialChristian Hengstenberg, Martin Unverdorben, Helge Möllmann, et al.
Journal of the American Heart Association|January 10, 2025
Epistaxis Versus Nonepistaxis Bleeding in Anticoagulated Patients With Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 TrialRobert S Semco, Regan W Bergmark, Sabina A Murphy, et al.
European Journal of Preventive Cardiology|October 25, 2025
Impact of weight/BMI on clinical and bleeding events in 26 805 atrial fibrillation patients on edoxaban from the Global ETNA-AF RegistryGiuseppe Boriani, Paulus Kirchhof, José Antonio Gordillo de Souza, et al.
Circulation Reports|March 11, 2024
Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation Patients From Asia　- One-Year Data From the Global ETNA-AF ProgramJong-Il Choi, Songsak Kiatchoosakun, Panyapat Jiampo, et al.
Journal of Interventional Cardiology|October 18, 2003
Comparison of a silicon carbide coated stent versus a noncoated stent in humans: the Tenax- versus Nir-Stent Study (TENISS)Martin Unverdorben, Katherine Sattler, Ralf Degenhardt, et al.
JAMA Cardiology|July 10, 2024
Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical TrialAndré Zimerman, Eugene Braunwald, Jan Steffel, et al.
Indian Heart Journal|November 12, 2013
The paclitaxel-eluting PTCA-balloon in combination with a cobalt-chromium stent in two different sequences to treat de novo coronary artery lesions: an angiographic follow up studyUpendra Kaul, Martin Unverdorben, Ralf Degenhardt, et al.
American Heart Journal|April 8, 2003
Comparison of a silicon carbide-coated stent versus a noncoated stent in human beings: the Tenax versus Nir Stent Study's long-term outcomeMartin Unverdorben, Babett Sippel, Ralf Degenhardt, et al.
Pageof 8

Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|September 24, 2013
Treatment of small coronary arteries with a paclitaxel-coated balloon catheter in the PEPCAD I study: are lesions clinically stable from 12 to 36 months?Martin Unverdorben, Franz X Kleber, Hubertus Heuer, et al.
Journal of the American Heart Association|May 15, 2025
Comparing Major Gastrointestinal Bleeding in Patients Receiving Edoxaban Versus Warfarin After Transcatheter Aortic Valve Replacement: Results From the Randomized ENVISAGE-TAVI AF TrialGeorge D Dangas, Martin Unverdorben, Johny Nicolas, et al.
The American Journal of Cardiology|July 20, 2024
Risk Factors of Ischemic Stroke in Patients With Atrial Fibrillation After Transcatheter Aortic Valve Implantation from the Randomized ENVISAGE-TAVI AF TrialChristian Hengstenberg, Martin Unverdorben, Helge Möllmann, et al.
Journal of the American Heart Association|January 10, 2025
Epistaxis Versus Nonepistaxis Bleeding in Anticoagulated Patients With Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 TrialRobert S Semco, Regan W Bergmark, Sabina A Murphy, et al.
European Journal of Preventive Cardiology|October 25, 2025
Impact of weight/BMI on clinical and bleeding events in 26 805 atrial fibrillation patients on edoxaban from the Global ETNA-AF RegistryGiuseppe Boriani, Paulus Kirchhof, José Antonio Gordillo de Souza, et al.
Circulation Reports|March 11, 2024
Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation Patients From Asia　- One-Year Data From the Global ETNA-AF ProgramJong-Il Choi, Songsak Kiatchoosakun, Panyapat Jiampo, et al.
Journal of Interventional Cardiology|October 18, 2003
Comparison of a silicon carbide coated stent versus a noncoated stent in humans: the Tenax- versus Nir-Stent Study (TENISS)Martin Unverdorben, Katherine Sattler, Ralf Degenhardt, et al.
JAMA Cardiology|July 10, 2024
Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical TrialAndré Zimerman, Eugene Braunwald, Jan Steffel, et al.
Indian Heart Journal|November 12, 2013
The paclitaxel-eluting PTCA-balloon in combination with a cobalt-chromium stent in two different sequences to treat de novo coronary artery lesions: an angiographic follow up studyUpendra Kaul, Martin Unverdorben, Ralf Degenhardt, et al.
American Heart Journal|April 8, 2003
Comparison of a silicon carbide-coated stent versus a noncoated stent in human beings: the Tenax versus Nir Stent Study's long-term outcomeMartin Unverdorben, Babett Sippel, Ralf Degenhardt, et al.
Pageof 8